PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Vitalant Research Institute, San Francisco, California, USA.\', \'Department of Laboratory Medicine, University of California, San Francisco, California, USA.\', \'Westat, Rockville, Maryland, USA.\', \'American Red Cross, Gaithersburg, Maryland, USA.\', \'Creative Testing Solutions, Tempe, Arizona, USA.\', \'New York Blood Center, New York, New York, USA.\', \'Blood Works Northwest, Seattle, Washington, USA.\', \'Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA.\', \'University of British Columbia, Victoria, British Columbia, Canada.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1093/cid/ciab537
?:doi
?:hasPublicationType
?:journal
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
is ?:pmid of
?:pmid
?:pmid
  • 34111244
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all